KIT and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, KIT has been implicated in CML pathogenesis, and KIT-expressing BCR-ABL-transduced murine myeloid cells are less sensitive to tyrosine kinase inhibitors.4, 5 Therefore, we postulated that PPFIA1, the target of miR-181a, may promote malignant phenotypes through activating the KIT signaling pathway in K562 cells.